BoboWV, CooperWO, SteinCM, et al.Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 2013; 70(10):1067–1075; doi: 10.1001/jamapsychiatry.2013.2053
2.
DelBelloMP, BrunsKM, BloomT, et al.A double-blind placebo-controlled pilot study of topiramate in manic adolescents treated with olanzapine. J Child Adolesc Psychopharmacol, 2023; 33(4):126–133; doi: 10.1089/cap.2022.0098
3.
GellerB, ZimermanB, WilliamsM, et al.Six-month stability and outcome of a prepubertal and early adolescent bipolar disorder phenotype. J Child Adolesc Psychopharmacol, 2000; 10(3):165–173; doi: 10.1089/10445460050167278
4.
HoneycuttDC, BlomTJ, RamseyLB, et al.Pharmacogenetic factors influence escitalopram pharmacokinetics and adverse events in youth with a family history of bipolar disorder: A Preliminary Study. J Child Adolesc Psychopharmacol, 2024; 34(1):42–51; doi: 10.1089/cap.2023.0073
5.
LyuN, RowanPJ, AbughoshS, et al.Trajectories and predictors for the development of clinically significant weight gain in children and adolescents prescribed second-generation antipsychotics. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2023.0071
6.
MoonE, KimE, WilliamsA. Initiation of aripiprazole lauroxil long-acting injectable in adolescents during hospitalization: A Case Series. J Child Adolesc Psychopharmacol, 2023; 33(10):433–438; doi: 10.1089/cap.2023.0049
7.
SilvermanAM, DimickMK, BartonJS, et al.Comparing symptoms of major depression in youth with confirmed versus suspected bipolar disorder. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2023.0090
8.
SinghMK, KelleyRG, HoweME, et al.Reward processing in healthy offspring of parents with bipolar disorder. JAMA Psychiatry, 2014; 71(10):1148–1156; doi: 10.1001/jamapsychiatry.2014.1031
9.
YanNE, DimickMK, KennedyKG, et al.Vascular endothelial growth factor polymorphism rs699947 is associated with neurostructural phenotypes in youth with bipolar disorder. J Child Adolesc Psychopharmacol, 2023; 33(6):243–254; doi: 10.1089/cap.2022.0083
10.
ZhuD, ZitoJM, GardnerJF, et al.Stimulant patterns, alone or with other psychotropic classes, in medicaid-insured youth continuously enrolled for 3–8 years. J Child Adolesc Psychopharmacol, 2024; 34(3):127–136; doi: 10.1089/cap.2023.0028
